JZY‑2233: A PSMA‑Targeted Degrader‑Antibody Conjugate for Advanced Prostate Cancer

Researchers have developed a new targeted therapy for advanced prostate cancer called JZY‑2233, a degrader‑antibody conjugate that homes in on prostate‑specific membrane antigen (PSMA) while delivering a highly potent CBP/p300 degrader directly to tumor cells. CBP and p300 are transcriptional coactivators that help the androgen receptor drive oncogenic gene programs in prostate cancer, and small‑molecule […]